Literature DB >> 19342441

A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease.

N A Verwey1, W M van der Flier, K Blennow, C Clark, S Sokolow, P P De Deyn, D Galasko, H Hampel, T Hartmann, E Kapaki, L Lannfelt, P D Mehta, L Parnetti, A Petzold, T Pirttila, L Saleh, A Skinningsrud, J C V Swieten, M M Verbeek, J Wiltfang, S Younkin, P Scheltens, M A Blankenstein.   

Abstract

BACKGROUND: Different cerebrospinal fluid (CSF) amyloid-beta 1-42 (Abeta(1-42)), total Tau (Tau) and Tau phosphorylated at threonine 181 (P-Tau) levels are reported, but currently there is a lack of quality control programmes. The aim of this study was to compare the measurements of these CSF biomarkers, between and within centres.
METHODS: Three CSF-pool samples were distributed to 13 laboratories in 2004 and the same samples were again distributed to 18 laboratories in 2008. In 2004 six laboratories measured Abeta(1-42), Tau and P-Tau and seven laboratories measured one or two of these marker(s) by enzyme-linked immunosorbent assays (ELISAs). In 2008, 12 laboratories measured all three markers, three laboratories measured one or two marker(s) by ELISAs and three laboratories measured the markers by Luminex.
RESULTS: In 2004, the ELISA intercentre coefficients of variance (interCV) were 31%, 21% and 13% for Abeta(1-42), Tau and P-Tau, respectively. These were 37%, 16% and 15%, respectively, in 2008. When we restricted the analysis to the Innotest (N = 13) for Abeta(1-42), lower interCV were calculated (22%). The centres that participated in both years (N = 9) showed interCVs of 21%, 15% and 9% and intra-centre coefficients (intraCV) of variance of 25%,18% and 7% in 2008.
CONCLUSIONS: The highest variability was found for Abeta(1-42). The variabilities for Tau and P-Tau were lower in both years. The centres that participated in both years showed a high intraCV comparable to their interCV, indicating that there is not only a high variation between but also within centres. Besides a uniform standardization of (pre)analytical procedures, the same assay should be used to decrease the inter/intracentre variation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19342441     DOI: 10.1258/acb.2009.008232

Source DB:  PubMed          Journal:  Ann Clin Biochem        ISSN: 0004-5632            Impact factor:   2.057


  52 in total

1.  The impact of cerebrospinal fluid biomarkers on the diagnosis of Alzheimer's disease.

Authors:  Sebastiaan Engelborghs; Nathalie Le Bastard
Journal:  Mol Diagn Ther       Date:  2012-06-01       Impact factor: 4.074

2.  Alzheimer disease: hippocampal volume loss and Alzheimer disease progression.

Authors:  Wiesje M van der Flier; Philip Scheltens
Journal:  Nat Rev Neurol       Date:  2009-07       Impact factor: 42.937

3.  Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI.

Authors:  Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Michal Figurski; Els Coart; Kaj Blennow; Holly Soares; Adam J Simon; Piotr Lewczuk; Robert A Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2011-02-11       Impact factor: 17.088

4.  Analytical and clinical performances of the automated Lumipulse cerebrospinal fluid Aβ42 and T-Tau assays for Alzheimer's disease diagnosis.

Authors:  Jean-Louis Bayart; Bernard Hanseeuw; Adrian Ivanoiu; Vincent van Pesch
Journal:  J Neurol       Date:  2019-06-10       Impact factor: 4.849

Review 5.  Biomarkers for the Early Detection and Progression of Alzheimer's Disease.

Authors:  Scott E Counts; Milos D Ikonomovic; Natosha Mercado; Irving E Vega; Elliott J Mufson
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

6.  Is it time for biomarker-based diagnostic criteria for prodromal Alzheimer's disease?

Authors:  Kaj Blennow; Henrik Zetterberg
Journal:  Alzheimers Res Ther       Date:  2010-04-30       Impact factor: 6.982

7.  cNEUPRO: Novel Biomarkers for Neurodegenerative Diseases.

Authors:  Philipp Spitzer; Hans Wolfgang Klafki; Kaj Blennow; Luc Buée; Hermann Esselmann; Sanna-Kaisa Herruka; Connie Jimenez; Peter Klivenyi; Piotr Lewczuk; Juan Manuel Maler; Katrin Markus; Helmut E Meyer; Chris Morris; Thorsten Müller; Markus Otto; Lucilla Parnetti; Hilkka Soininen; Susanna Schraen; Charlotte Teunissen; Laszlo Vecsei; Henrik Zetterberg; Jens Wiltfang
Journal:  Int J Alzheimers Dis       Date:  2010-09-19

8.  Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid.

Authors:  Maria Bjerke; Erik Portelius; Lennart Minthon; Anders Wallin; Henrik Anckarsäter; Rolf Anckarsäter; Niels Andreasen; Henrik Zetterberg; Ulf Andreasson; Kaj Blennow
Journal:  Int J Alzheimers Dis       Date:  2010-07-15

9.  CSF Biomarkers Profile in CADASIL-A Model of Pure Vascular Dementia: Usefulness in Differential Diagnosis in the Dementia Disorder.

Authors:  Patrizia Formichi; Lucilla Parnetti; Elena Radi; Gabriele Cevenini; Maria Teresa Dotti; Antonio Federico
Journal:  Int J Alzheimers Dis       Date:  2010-08-18

10.  Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease.

Authors:  Niklas Mattsson; Henrik Zetterberg; Kaj Blennow
Journal:  Int J Alzheimers Dis       Date:  2010-07-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.